[Rare tumors: Angiosarcoma].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): El-Ghazzi N;El-Ghazzi N;El-Ghazzi N; Bay JO; Bay JO; Bay JO
  • Source:
    Bulletin du cancer [Bull Cancer] 2023 May; Vol. 110 (5), pp. 581-588. Date of Electronic Publication: 2023 Mar 25.
  • Publication Type:
    English Abstract; Journal Article
  • Language:
    French
  • Additional Information
    • Transliterated Title:
      Tumeurs rares : angiosarcome.
    • Source:
      Publisher: Elsevier Country of Publication: France NLM ID: 0072416 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1769-6917 (Electronic) Linking ISSN: 00074551 NLM ISO Abbreviation: Bull Cancer Subsets: MEDLINE
    • Publication Information:
      Publication: Jan. 2015- : Paris : Elsevier
      Original Publication: Paris : Masson
    • Subject Terms:
      Hemangiosarcoma*/pathology ; Hemangiosarcoma*/surgery ; Sarcoma*/pathology ; Breast Neoplasms*/drug therapy; Humans ; Female ; Paclitaxel/therapeutic use ; Prognosis
    • Abstract:
      Angiosarcomas are a rare subtype representing 1-2% of soft tissue sarcomas. Risk factors are rarely elucidated but radiotherapy and lymphedema are the most common ones, usually following local treatment for local breast cancer. Despite the improvement of our knowledge, the prognosis remains poor with 35-40% of 5 year-overall survival. Local treatment when feasible should include a R0 surgery completed with adjuvant radiation. When metastatic, front lines chemotherapies include doxorubicine or weekly paclitaxel. If possible, in oligometastatic patients, metastasectomy should always be considered allowing the best responses. The knowledge of angiosarcoma's biology is rapidly increasing and new biomarkers are emerging. The use of immunotherapy in particular subtypes including head and neck angiosarcomas shows promising results. The model of the angiosarcoma project, a patient-participating study, seems to be an excellent way to study rare tumors. We should focus our efforts on understanding the underlying molecular biology to propose the best precision medicine for those patients.
      (Copyright © 2023 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
    • Contributed Indexing:
      Keywords: Angiosarcoma; Angiosarcome; Biologie moléculaire; Chemotherapy; Chimiothérapie; Immunotherapy; Immunothérapie; Molecular biology; Sarcome des tissus mous; Soft tissue sarcoma
    • Accession Number:
      P88XT4IS4D (Paclitaxel)
    • Publication Date:
      Date Created: 20230327 Date Completed: 20230509 Latest Revision: 20230509
    • Publication Date:
      20230509
    • Accession Number:
      10.1016/j.bulcan.2023.03.002
    • Accession Number:
      36973135